



Patent application of

Rolland Hebert

For

DIASTERIOMERS OF S-ADENOSYL-L-METHIONINE

Field of the Invention

The present invention relates to novel compositions of matter containing substantially optically pure diastereomers of S-adenosyl-l-methionine. These compositions possess potent activity in treating various conditions involving hypomethylation and transulfuration reactions.

Background-Cross-References to Related Application

This application claims the benefit of Provisional Patent Application Serial Number: 60/229151 filed on August 30, 2000.

Technical field:

This patent relates to novel compositions of matter containing optically pure diastereomers of S-adenosyl-l-methionine (SAM-e), defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine and to therapeutic uses of these new compositions. More particularly, the invention relates to the substantially optically pure diastereomer (S,S)- S-adenosyl-l-methionine, defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine, pharmaceutically acceptable salts and pharmaceutical compositions that contain them as active principles.

Background of the invention:

Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L or R and S are used to denote the absolute configuration of the molecule about its chiral center. The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these compounds, called stereoisomers, are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture. A compound with more than one chiral center is a diastereomer. S-adenosyl-l-methionine is a diastereomer.

Stereochemical purity is of importance in the field of pharmaceuticals, where 12 of the 20 most prescribed drugs exhibit chirality. A case in point is provided by the L-form of the beta-adrenergic blocking agent, propranolol, which is known to be 100 times more potent than the D-enantiomer.

Furthermore, optical purity is important since certain isomers may actually be deleterious rather than simply inert. For example, it has been suggested that the D-enantiomer of thalidomide was a safe and effective sedative when prescribed for the control of morning sickness during pregnancy, and that the corresponding L-enantiomer was a potent teratogen.

S-adenosyl-l-methionine is a naturally occurring substance that is present in all living organisms and has a number of very important biological functions. Among these functions are the following: methyl group donor in transmethylation reactions (it is the sole methyl group donor in such reactions-including methylation of DNA, proteins, hormones, catechol and

indoleamines and phosphatidylethanolamine to phosphatidylcholine); it is a substrate of an enzyme lyase that converts S-adenosyl-l-methionine to the molecule methylthioadenosine and homoserine; it is an aminobutyric chain donor to tRNA; it is an aminoacidic chain donor in the biosynthesis of biotin; S-adenosyl-l-methionine, after decarboxylation, is the donor of aminopropyl groups for the biosynthesis of neuroregulatory polyamines spermidine and spermine. (Zappia et al (1979), Biomedical and Pharmacological roles of Adenosylmethionine and the Central Nervous System, page 1, Pergamon Press. NY.)

S-adenosyl-l-methionine has been used clinically in the treatment of liver disease (Friedel H, Goa, K.L., and Benfield P., (1989), S-adenosyl-l-methionine: a review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism. *Drugs*. 38, 389-416), arthritis (Di Padova C, (1987), S-adenosyl-l-methionine in the treatment of osteoarthritis: review of the clinical studies. *Am J. Med.* 83, (Suppl. 5), 6-65), and depression (Kagan, B, Sultzer D.L., Rosenlicht N and Gerner R. (1990), Oral S-adenosyl-l-methionine in depression: a randomized, double blind, placebo-controlled trial. *Am. J. Psychiatry* 147, 591-595.) Alzheimer's patients have reduced cerebral spinal fluid levels of S-adenosyl-l-methionine (Bottiglieri et al, (1990), Cerebrospinal fluid S-adenosyl-l-methionine in depression and dementia: effects of treatment with parenteral and oral S-adenosyl-l-methionine. *J. Neurol. Neurosurg. Psychiatry* 53, 1096-1098.) In a preliminary study, S-adenosyl-l-methionine was able to produce cognitive improvement in patients with Alzheimer's disease. (Bottiglieri et al (1994), The clinical potential of admetionine (S-adenosyl-l-methioinine) in neurological disorders. *Drugs* 48, 137-152.) S-adenosyl-l-methionine brain levels in patients with Alzheimer's disease are also severely decreased. (Morrison et al, (1996), Brain S-adenosyl-l-methionine levels are severely decreased in Alzheimer's disease, *Journal of Neurochemistry*, 67, 1328-1331.) Patients with Parkinson's disease have also been shown to have significantly decreased blood levels of S-adenosyl-l-methionine. (Cheng et al, (1997), Levels of L-methionine S-adenosyltransferase activity in

erythrocytes and concentrations of S-adenosyl-l-methionine and S-adenosylhomocysteine in whole blood of patients with Parkinson's disease. *Experimental Neurology* 145, 580-585.)

S-adenosyl-l-methionine levels in patients treated with the antineoplastic drug methotrexate are reduced. Neurotoxicity associated with this drug may be attenuated by co-administration of S-adenosyl-l-methionine. (Bottiglieri et al (1994), The Clinical Potential of Ademetionine (S-adenosyl-l-methionine) in neurological disorders, *Drugs*, 48 (2), 137-152.)

Cerebral spinal fluid levels of S-adenosyl-l-methionine have been investigated in HIV AIDS dementia Complex/ HIV encephalopathy and found to be significantly lower than in non-HIV infected patients. (Keating et al (1991), Evidence of brain methyltransferase inhibition and early brain involvement in HIV positive patients *Lancet*: 337:935-9.)

De La Cruz et al have shown that S-adenosyl-l-methionine, chronically administered, can modify the oxidative status in the brain by enhancing anti-oxidative defenses. (De La Cruz et al, (2000), Effects of chronic administration of S-adenosyl-l-methionine on brain oxidative stress in rats. *Naunyn-Schmiedeberg's Archives Pharmacol* 361: 47-52.) This is similar to results obtained with S-adenosyl-l-methionine in liver and kidney tissue. Thus S-adenosyl-l-methionine would be useful as an antioxidant.

Oral S-adenosyl-l-methionine administration to patients with and without liver disease has resulted in increases in liver glutathione levels. (Vendemiale G et al, (1989), Effect of oral S-adenosyl-l-methionine on hepatic glutathione in patients with liver disease. *Scand J Gastroenterol*; 24: 407-15. Oral administration of S-adenosyl-l-methionine to patients suffering from intrahepatic cholestasis had improvements in both the pruritus as well as the biochemical markers of cholestasis. (Giudici et al, The use of admetionine (S-adenosyl-l-methionine) in the treatment of cholestatic liver disorders. Meta-analysis of clinical trials. In: Mato et al editors. *Methionine Metabolism: Molecular Mechanism and Clinical Implications*. Madrid: CSIC Press; 1992 pp 67-79.) Oral S-adenosyl-l-methionine administration to patients suffering from

primary fibromyalgia resulted in significant improvement after a short term trial. (Tavoni et al, Evaluation of S-adenosylmethioine in Primary Fibromaylgia. The American Journal of Medicine, Vol 83 (suppl 5A), pp 107-110, 1987.) S-adenosyl-l-methionine has been used for the treatment of osteoarthritis as well. (Koenig B. A long-term (two years) clinical trial with S-adenosyl-l-methionine for the treatment of osteoarthritis. The American Journal of Medicine, Vol 83 (suppl 5A), Nov. 20, 1987 pp 89-94)

S-adenosyl-l-methionine is clinically useful in many apparently unrelated areas because of its important function in basic metabolic processes. One of its most striking clinical uses is in the treatment of alcoholic liver cirrhosis that, until now, remained medically untreatable. Mato et al demonstrated the ability of oral S-adenosyl-l-methionine in alcoholic liver cirrhosis to decrease the overall mortality and/or progression to liver transplant by 29% vs 12% as compared with a placebo treated group. (Mato et al (1999), S-adenosyl-l-methionine in alcohol liver cirrhosis: a randomized, placebo-controlled, double blind, multi-center clinical trial, Journal of Hepatology, 30, 1081-1089.)

S-adenosyl-l-methionine also attenuates the damage caused by tumor necrosis factor alpha and can also decrease the amount of tumor necrosis factor alpha secreted by cells. Consequently, conditions in which this particular inflammatory factor is elevated would benefit from the administration of S-adenosyl-l-methionine. (Watson WH, Zhao Y, Chawla RK, (1999) Biochem J Aug 15; 342 (Pt 1):21-5. S-adenosyl-l-methionine attenuates the lipopolysaccharide-induced expression of the gene for tumour necrosis factor alpha.) S-adenosyl-l-methionine has also been studied for its ability to reduce the toxicity associated with administration of cyclosporine A, a powerful immunosuppressor. (Galan A, et al, Cyclosporine A toxicity and effect of the S-adenosyl-l-methionine, Ars Pharmaceutica, 40:3; 151-163, 1999.)

S-adenosyl-l-methionine, incubated in vitro with human erythrocytes, penetrates the cell membrane and increases ATP within the cell thus restoring the cell shape. (Friedel et al, S-

adenosyl-l-methionine: A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism, *Drugs* 38 (3):389-416, 1989)

S-adenosyl-l-methionine has been studied in patients suffering from migraines and found to be of benefit. (Friedel et al, S-adenosyl-l-methionine: A review of its pharmacological properties and therapeutic potential in liver dysfunction and affective disorders in relation to its physiological role in cell metabolism, *Drugs* 38 (3): 389-416, 1989)

S-adenosyl-l-methionine has been administered to patients with peripheral occlusive arterial disease and was shown to reduce blood viscosity, chiefly via its effect on erythrocyte deformability.

S-adenosyl-l-methionine is commercially available using fermentation technologies that result in S-adenosyl-l-methionine formulations varying between 60 and 80 % purity. (That is, the final product contains 60-80% of the active or (S,S)-S-adenosyl-l-methionine and 20-40% of the inactive or (R,S) -S-adenosyl-l-methionine.) (Gross, A., Geresh, S., and Whitesides, Gm (1983) *Appl. Biochem. Biotech.* 8, 415.) Enzymatic synthetic methodologies have been reported to yield the inactive isomer in concentrations exceeding 60%. (Matos, JR, Rauschel FM, Wong, CH. S-adenosyl-l-methionine: Studies on Chemical and Enzymatic Synthesis. *Biotechnology and Applied Biochemistry* 9, 39-52 (1987). Enantiomeric separation technologies have been reported to resolve the pure active diastereomer of S-adenosyl-l-methionine. (Matos, JR, Rauschel FM, Wong, CH. S-adenosyl-l-methionine: Studies on Chemical and Enzymatic Synthesis. *Biotechnology and Applied Biochemistry* 9, 39-52 (1987; Hoffman, *Chromatographic Analysis of the Chiral and Covalent Instability of S-adenosyl-l-methionine*, *Biochemistry* 1986, 25 4444-4449: Segal D and Eichler D, The Specificity of Interaction between S-adenosyl-l-methionine and a nucleolar 2-O-methyltransferase, *Archives of Biochemistry and Biophysics*, Vol. 275, No. 2, December, pp. 334-343, 1989) Newer

separation technologies exist to resolve enantiomers and diastereomers on a large commercial production scale at a very economic cost. In addition, it would be conceivable to synthesize the biologically active diastereomer using special stereoselective methodologies but this has not been accomplished to date.

De la Haba first showed that the sulfur is chiral and that only one of the two possible configurations was synthesized and used biologically. (De la Haba et al J. Am. Chem. Soc. 81, 3975-3980, 1959) Methylation of RNA and DNA is essential for normal cellular growth. This methylation is carried out using S-adenosyl-l-methionine as the sole or major methyl donor with the reaction being carried out by a methyltransferase enzyme. Segal and Eichler showed that the enzyme bound (S, S)-S-adenosyl-l-methionine 10 fold more tightly than the biologically inactive (R,S)-S-adenosyl-l-methionine thus demonstrating a novel binding stereospecificity at the sulfur chiral center. Other methyltransferases have been reported to bind (R, S)-S-adenosyl-l-methionine to the same extent as (S, S)-S-adenosyl-l-methionine and thus (R,S)-S-adenosyl-l-methionine could act as a competitive inhibitor of that enzyme. (Segal D and Eichler D, The Specificity of Interaction between S-adenosyl-l-methionine and a nucleolar 2-O-methyltransferase, Archives of Biochemistry and Biophysics, Vol. 275, No. 2, December, pp. 334-343, 1989; Borchardt RT and Wu YS, Potential inhibitors of S-adenosyl-l-methionine-dependent methyltransferases. Role of the Asymmetric Sulfonium Pole in the Enzymatic binding of S-adenosyl-l-methionine, Journal of Medicinal Chemistry, 1976, Vol 19, No. 9, 1099-1103.)

S-adenosyl-l-methionine (whether in its optically pure diastereomeric form or in a racemic mixture) presents certain difficult problems in terms of its stability at ambient temperature that result in degradation of the molecule to undesirable degradation products. S-adenosyl-l-methionine (and thus its diastereomers) must be further stabilized since it exhibits intramolecular instability that causes the destabilization and breakdown of the molecule at both high as well as ambient temperatures. S-adenosyl-l-methionine has therefore been the subject

of many patents directed both towards obtaining new stable salts, and towards the provision of preparation processes that can be implemented on an industrial scale. The present patent thus envisions the use of any of the salts of S-adenosyl-l-methionine already disclosed in the prior art to stabilize the diastereomeric forms of S-adenosyl-l-methionine. Examples of such salts disclosed in the prior art include the following: a lipophilic salt of S-adenosyl-l-methionine of the formula S-adenosyl-l-methionine.^{sup.n+} [R—CO—NH—(CH_{sub.2})_{sub.2} —SO.^{sup.-}_{sub.3}]_{sub.n} in which R-CO is a member selected from the group consisting of C_{sub.12}-C_{sub.26} saturated and unsaturated, linear and branched acyl and C_{sub.12} -C_{sub.26} cycloalkyl-substituted acyl, and n is an integer from 3 to 6 according to the S-adenosyl-l-methionine charge; double salts corresponding to the formula S-adenosyl-l-methionine.^{sup.+}.HSO._{sub.4}^{sup.-}.H._{sub.2} SO._{sub.4} .2 CH._{sub.3} C._{sub.6} H._{sub.4} SO._{sub.3} H. ; salts (S, S)-s-adenosyl-l-methionine with sulphonic acids selected from the group consisting of methanesulphonic, ethanesulphonic, 1-n-dodecanesulphonic, 1-n-octadecanesulphonic, 2-chloroethanesulphonic, 2-bromoethanesulphonic, 2-hydroxyethanesulphonic, 3-hydroxypropanesulphonic, d,l,d,l-10-camphorsulphonic, d,l,d,l-3-bromocamphor-10-sulphonic, cysteic, benzenesulphonic, p-chlorobenzenesulphonic, 2-mesitylbenzenesulphonic, 4-biphenylsulphonic, 1-naphthalenesulphonic, 2-naphthalenesulphonic, 5-sulphosalicylic, p-acetylbenzenesulphonic, 1,2-ethanedisulphonic, methanesulphonic acid, ethanesulphonic acid, 1-n-dodecanesulphonic acid, 1-n-octadecanesulphonic acid, 2-chloroethanesulphonic acid, 2-bromoethanesulphonic acid, 2-hydroxyethanesulphonic acid, d,l,d,l-10-camphorsulphonic acid, d,l,d,l-3-bromocamphor-10-sulphonic acid, cysteic acid, benzenesulphonic acid, 3-hydroxypropanesulphonic acid, 2-mesitylbenzenesulphonic acid, p-chlorobenzenesulphonic acid, 4-biphenylsulphonic acid, 2-naphthalenesulphonic acid, 5-sulphosalicylic acid, 1,2-ethanedisulphonic acid, p-acetylbenzenesulphonic acid, 1-naphthalenesulphonic acid, o-benzenedisulphonic and chondroitinesulphuric acids, and double salts of said acids with sulphuric acid; S-adenosyl-l-methionine or a pharmaceutically acceptable salt thereof and an effective amount of a lithium salt selected from the group consisting of lithium chloride, lithium bromide, lithium iodide, lithium sulfate, lithium nitrate, lithium phosphate, lithium

borate, lithium carbonate, lithium formate, lithium acetate, lithium citrate, lithium succinate and lithium benzoate; water-soluble salt of a bivalent or trivalent metal is a member selected from the group consisting of calcium chloride, ferric chloride, magnesium chloride, and magnesium sulfate; the salt of S-adenosyl-l-methionine is a member selected from the group consisting of salts of S-adenosyl-l-methionine with hydrochloric acid, sulfuric acid, phosphoric acid, formic acid, acetic acid, citric acid, tartaric acid, and maleic acid; and a double salt of S-adenosyl-l-methionine with said acids; a salt of S-adenosyl-l-methionine and a water-soluble polyanionic substance selected from the group consisting of a polyphosphate, metaphosphate, polystyrene sulfonate, polyvinyl sulfonate, polyvinyl sulfate, polyvinyl phosphate, and polyacrylate wherein the stoichiometric ratio of mols of S-adenosyl-l-methionine to gram-equivalent of the polyanionic substance is from 0.1:1 to 0.5; a salt of S-adenosyl-l-methionine wherein the polyanionic substance is a polyphosphate, para-polystyrene sulfonate or metaphosphate; a salt of the general formula: S-adenosyl-l-methionine. n R(O).sub.m (SO.sub.3 H) p (I) where m can be zero or 1; n is 1.5 when p is 2, and is 3 when p is 1; R is chosen from the group consisting of alkyl, phenylalkyl and carboxyalkyl, in which the linear or branched alkyl chain contains from 8 to 18 carbon atoms, and in particular for producing S-adenosyl-l-methionine salts of sulphonic acids, or of sulphuric acid esters, or of dioctylsulphosuccinic acid. However the more preferred salts of the S-adenosyl-l-methionine diastereomers are chosen from the group consisting of salts of S-adenosyl-l-methionine diastereomers with sulfuric acid, p-toluenesulfonic acid, 1,4-butanedisulphonic acid.

Prior Art

Many patents exist disclosing salts of S-adenosyl-l-methionine that stabilize the molecule but none discloses the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 2,969,353, Shunk et al, January 24, 1962, discloses a method for the preparation of S-adenosyl-l-methionine and a stable salt of S-adenosyl-l-methionine but not the use of an

optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 3,707,536, Haid et al, December 26, 1972, discloses a new S-adenosyl-l-methionine bisulfate salt but not the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 3,893,999, Fiecchi, July 8, 1975, discloses a new salt of S-adenosyl-l-methionine made with tri-p-toluensulphonate but not the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 5,102,791, Gennari, April 7, 1992, discloses, among others, a 1,4-butanedisulfonate salt of S-adenosyl-l-methionine but not the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,028,183, Fiecchi, June 7, 1977, discloses, among others, p-toluene sulfonate as a means to stabilize the S-adenosyl-l-methionine molecule but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,764,603, Zappia, August 16, 1988, discloses the use of polyanions such as polyphosphates, polyvinylsulfonates-sulfates or phosphates, polyacrylates, and polystyrene sulfonates. However, this patent does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine.

United States Patent 6,117,849, Zimmermann, et al. September 12, 2000, discloses the use of S-adenosyl-l-methionine complexed with nucleosides as HIV inhibitors but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine for any other condition nor a diastereomer of S-adenosyl-l-methionine uncomplexed to another molecule. United States Patent 4,465,672, Gennari, August 14, 1984, discloses new S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 3,954,726, Fiecchi, May 4, 1976, discloses double salts of S-adenosyl-l-methionine but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,057,686, Fiecchi, November 8, 1977, discloses stable salts of S-adenosyl-l-methionine but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,109,079 Kawahara, et al., August 22, 1978, discloses new stable S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent

4,242,505, Kawahara, et al. December 30, 1980, discloses new stabilizing salts of S-adenosyl-l-methionine but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,369,177, Kozaki, et al. January 18, 1983, discloses new stable S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,543,408, Gennari, September 24, 1985, discloses new S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,558,122, Gennari, December 10, 1985, discloses new S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,764,603, Zappia, et al. August 16, 1988, discloses the use of new salts of S-adenosyl-l-methionine but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 4,990,606, Gennari, February 5, 1991, discloses new salts of S-adenosyl-l-methionine but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 5,073,546, Zappia, et al. December 17, 1991, discloses new salts of S-adenosyl-l-methionine but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 5,114,931, Gennari, May 19, 1992, discloses injectable S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 5,128,249, Gennari, July 7, 1992, discloses new S-adenosyl-l-methionine salts but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine. United States Patent 5,196,402, Braganza, et al. March 23, 1993, discloses the use of S-adenosyl-l-methionine for certain clinical uses but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine.

United States Patent 5,466,678, Kawabata, et al. November 14, 1995, discloses the use S-adenosyl-l-methionine to decrease the side effects of chemotherapy but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine to accomplish this. United States Patent 5,137,712, Kask et al, August 11, 1992 discloses the use of S-adenosyl-l-

methionine to reverse or prevent side effects of neuroleptic treatment but does not disclose the use of an optically pure diastereomer of S-adenosyl-l-methionine.

Administration of optically pure diastereomers of S-adenosyl-l-methionine salts of the present invention would have significant utility over a wide range of disorders or conditions associated with low levels of S-adenosyl-l-methionine. Since the two diastereomeric forms of S-adenosyl-l-methionine of the present invention do not exhibit the same biological activity but rather that the (R, S) S-adenosyl-l-methionine diastereomer exhibits no biological activity (or even competitive inhibition), it is therefore necessary for a rational pharmaceutical therapy to use the more active diastereomeric form of S-adenosyl-l-methionine. In this regard, and in view of the (R, S)-S-adenosyl-l-methionine diastereomer to act as a competitive inhibitor of (S, S,) S-adenosyl-l-methionine in methyltransferase reactions, a more ideal S-adenosyl-l-methionine composition would be the substantially optically pure biologically active (S, S)- S-adenosyl-l-methionine form or a defined non-racemic ratio of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine.

It is an object of the present invention to provide new compositions of S-adenosyl-l-methionine containing substantially pure biologically active (S, S) S-adenosyl-l-methionine or a defined non-racemic ratio of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine. It is a further object of the present invention to provide such compositions that provide treatment or prevention of conditions that are related to lowering S-adenosyl-l-methionine levels. It is a still further object of the present invention to provide such compositions having good stability.

Accordingly, there is need in the art for new, substantially optically pure diastereomeric forms of S-adenosyl-l-methionine as well as methods related to the use of such substantially optically pure diastereomeric forms of S-adenosyl-l-methionine to increase blood and other tissue and fluid levels of S-adenosyl-l-methionine and to treat conditions which result from low blood and

tissue levels of S-adenosyl-l-methionine. The author of this present invention fulfills these needs, and provides further related advantages.

Summary of the invention:

Briefly stated, the present invention discloses compositions of substantially optically pure diastereomeric forms of S-adenosyl-l-methionine, defined non-racemic ratios of (S,S)-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine and methods for the use thereof. These new substantially optically pure diastereomeric forms of S-adenosyl-l-methionine of this present invention have utility in increasing blood and other tissue or fluid levels of S-adenosyl-l-methionine, as well as treating or preventing a wide variety of conditions associated with low blood or other tissue or fluid levels of S-adenosyl-l-methionine and inhibit tumor necrosis factor alpha. Thus in one embodiment, a substantially optically pure diastereomeric form of S-adenosyl-l-methionine salt is administered to a warm-blooded animal in need thereof to increase S-adenosyl-l-methionine levels. In another embodiment, a substantially optically pure diastereomeric form of S-adenosyl-l-methionine salt is administered to a warm-blooded animal in need thereof to prevent or treat a condition associated with low levels of S-adenosyl-l-methionine. In yet a further embodiment, a substantially optically pure diastereomeric form of S-adenosyl-l-methionine salt is administered to a warm blooded animal to prevent and or treat the following conditions: aging, aging of the skin, Alzheimer's disease, rheumatoid arthritis, osteoarthritis, both as an anti-inflammatory as well as to promote new cartilage formation, cancer, conditions of hypomethylation, mitochondrial diseases, hypomethylation of DNA and RNA, nerve damage associated with HIV/AIDS, anxiety, attention deficit disorder and ADHD, sleep regulation, organ preservation for transplant industry, dyslipidemias, excess sebum production, migraines, bile dysfunction caused by pregnancy and use of contraceptive medications, depression, acute and chronic liver disease, cirrhosis of the liver, ischemic reperfusion injury, Parkinson's disease, memory disturbances, memory loss, pancreatitis, intrahepatic cholestasis, inflammation, pain, side effects of administration of chemotherapy,

liver disease associated with administration of total parenteral nutrition, liver dysfunction, low tissue levels of glutathione, administration of neuroleptic drugs, administration of cyclosporin A, asthma, alcohol withdrawal,

Detailed description of the invention:

As mentioned above, this invention is generally directed to compositions of a substantially optically pure diastereomeric form of S-adenosyl-l-methionine salts and to defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine. Such new optically pure diastereomeric forms of S-adenosyl-l-methionine salts, when administered to a warm blooded animal in need thereof, have utility in the prevention or treatment of conditions associated with low levels of S-adenosyl-l-methionine in warm blooded animals, including humans.

As used herein, the term "conditions" includes diseases, injuries, disorders, indications and/or afflictions that are associated with decreased levels of S-adenosyl-l-methionine. The term "treat" or "treatment" means that the symptoms associated with one or more conditions associated with low levels of S-adenosyl-l-methionine are alleviated or reduced in severity or frequency and the term "prevent" means that subsequent occurrences of such symptoms are avoided or that the frequency between such occurrences is prolonged.

The substantially optically pure diastereomeric forms of S-adenosyl-l-methionine salts of this invention or defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine may be used to prevent and/or treat a variety of conditions associated with lowered levels of S-adenosyl-l-methionine. Due to its ubiquitous distribution in mammalian tissue, S-adenosyl-l-methionine is associated with a variety of conditions: aging, aging of the skin, Alzheimer's disease, rheumatoid arthritis, osteoarthritis, both as an anti-inflammatory as well as to promote new cartilage formation, cancer, conditions of hypomethylation, mitochondrial diseases, hypomethylation of DNA and RNA, HIV/AIDS, anxiety, attention

deficit disorder and ADHD, sleep regulation, organ preservation for transplant industry, dyslipidemias, excess sebum production, migraines, bile dysfunction caused by pregnancy and use of contraceptive medications, depression, acute and chronic liver disease, cirrhosis of the liver, ischemic reperfusion injury, Parkinson's disease, memory disturbances, memory loss, pancreatitis, intrahepatic cholestasis, inflammation, pain, side effects of administration of chemotherapy, liver disease associated with administration of total parenteral nutrition, liver dysfunction, low tissue levels of glutathione, administration of neuroleptic drugs, administration of cyclosporin A, asthma, alcohol withdrawal, .

Accordingly, substantially optically pure diastereomeric forms of S-adenosyl-l-methionine salts of this invention or defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine are effective in preventing and/or treating the above conditions due to their ability to increase S-adenosyl-l-methionine levels. To this end, substantially optically pure diastereomeric forms of S-adenosyl-l-methionine salts of the present invention or defined non-racemic ratios of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine may be used for pharmaceutical, prophylactic and/or cosmetic purposes, and are administered to a warm-blooded animal in an effective amount to achieve a desired result.

In the case of pharmaceutical administration, an effective amount is a quantity sufficient to treat the symptoms of a condition and/or the underlying condition itself. An effective amount in the context of prophylactic administration means an amount sufficient to avoid or delay the onset of a condition and/or its symptoms. Lastly, an effective amount with regard to cosmetic administration is an amount sufficient to achieve the desired cosmetic result.

In a preferred embodiment, the substantially optically pure diastereomeric forms of S-adenosyl-l-methionine salts of the present invention or a non-racemic mixture of (S,S)-S-adenosyl-l-methionine and (R,S)-S-adenosyl-l-methionine are administered to a warm-blooded animal as a pharmaceutical, prophylactic or cosmetic composition containing at least one substantially

optically pure diastereomeric forms of S-adenosyl-l-methionine salt or a non-racemic mixture of (S,S)-S-adenosyl-l-methionine and (R,S)-S-adenosyl-l-methionine in combination with at least one pharmaceutically, prophylactically or cosmetically acceptable carrier or diluent. Administration may be accomplished by systemic or topical application, with the preferred mode dependent upon the type and location of the conditions to be treated. Frequency of administration may vary, and is typically accomplished by daily administration.

In another embodiment, a pharmaceutical composition of the non-racemic ratio of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine is preferably from about 80.01% to about 100% of (S,S)-S-adenosyl-l-methionine to about 19.09% to about 0.0% by weight of (R,S)-S-adenosyl-l-methionine.

In yet another embodiment, a pharmaceutical composition of the non-racemic ratio of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine is more preferably from about 80.01% to about 96.09% of (S,S)-S-adenosyl-l-methionine to about 19.09% to about 3.01% by weight of (R,S)-S-adenosyl-l-methionine.

In yet a further embodiment, a pharmaceutical composition of the non-racemic ratio of (S,S)-S-adenosyl-l-methionine to (R,S)-S-adenosyl-l-methionine is most preferably from about 80.01% to about 95% of (S,S)-S-adenosyl-l-methionine to about 19.09% to about 5% by weight of (R,S)-S-adenosyl-l-methionine.

Systemic administration may be achieved, for example, by injection (e.g., intramuscular, intravenous, subcutaneous or intradermal) or oral delivery of the composition to the warm-blooded animal. Suitable carriers and diluents for injection are known to those skilled in the art, and generally are in the form of an aqueous solution containing appropriate buffers and preservatives. Oral delivery is generally accomplished by formulating the composition in a liquid or solid form, such as a tablet or capsule, by known formulation techniques.

Topical administration may be accomplished, for example, by formulating the composition as solution, cream, gel, ointment, powder, paste, gum or lozenge using techniques known to those skilled in the formulation field. As used herein, topical administration includes delivery of the composition to mucosal tissue of the mouth, nose and throat by, for example, spray or mist application, as well as to the vagina and rectum by, for example, suppository application.

The following example illustrates the synthetic process by which the new diastereomeric S-adenosyl-l-methionine salts may be made. In addition, the example shows how these new S-adenosyl-l-methionine salts may be used clinically. This example is given to illustrate the present invention, but not by way of limitation. Accordingly, the scope of this invention should be determined not by the embodiment illustrated, but rather by the appended claims and their legal equivalents.

EXAMPLE 1

1. (S, S)-S-adenosyl-l-methionine was prepared according to the method of Hoffman (Hoffman, Chromatographic Analysis of the Chiral and Covalent Instability of S-adenosyl-l-methionine, Biochemistry 1986, 25 4444-4449). Diastereomerically pure (S,S)-S-adenosyl-l-methionine was stabilized according to Fiecchi (United States Patent 4,028,183, June 7, 1977) using p-toluene sulfonate as the stabilizing agent.

(S, S)-S-adenosyl-l-methionine p-toluene sulfonate 400 mg was administered twice daily in an open, non-blind study of 10 volunteers who gave informed consent. All patients had normal results on pre-study medical examinations, including laboratory examinations. Patients received 400 mg of (S, S) -S-adenosyl-l-methionine p-toluene sulfonate in an enteric-coated tablet form twice daily for 14 days or until remission of depression symptoms. The 10 patients satisfied the DSM-III criteria for a major depressive episode. Patients' symptoms were

monitored daily using the Hamilton Rating Scale for Depression. 9 patients completed the study. (One patient declined to continue the study after beginning.) Eight of the nine patients who completed the trial improved over the 14 days. One patient had no change at all. No side effects were noted or reported by any of the patients nor as measured by laboratory or physical examination. (S, S)-S-adenosyl-l-methionine p-toluene sulfonate 400 mg twice daily appeared to be safe and effective in this small, non-blinded study of depression.